Key facts
- Notable investors include iAccel (Seongnam-si).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for MADI
- ·The full record, as it builds
Funding rounds
No funding rounds for MADI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MADI
Developer of a digital twin clinical trial platform designed to revolutionize drug development with AI digital twin technology. The company's platform creates digital twins using generative AI technology with virtual control groups and supports the entire clinical trial process from study design to data management with AI, enabling pharmaceutical companies to reduce clinical trial duration and address control group recruitment challenges.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2025
- Website
- madidt.com/
- Ownership
- Privately Held (backing)
MADI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MADI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MADI in its N-PORT filings yet. We sweep new filings monthly.